Safety and Effectiveness of New Biologic Therapy in Severe Asthma

Abstract

Background: Severe asthma remains a challenging condition, characterized by frequent exacerbations, persistent airflow limitation, and reliance on systemic corticosteroids, which carry significant long-term risks. Biologic therapies targeting specific inflammatory pathways have emerged as promising interventions to improve disease control and reduce treatment-related adverse effects. Evaluating their effectiveness and safety in real-world populations is essential to inform clinical practice. Objective: This study aimed to assess the impact of a new biologic therapy on exacerbation rates, lung function, symptom control, and corticosteroid reduction in patients with severe asthma, while evaluating its safety and tolerability over six months. Methods: A randomized controlled trial was conducted in the Urban Region Sindh involving 60 adult patients with severe asthma. Participants were randomly assigned to receive either biologic therapy in addition to standard care (n=30) or standard care alone (n=30). Baseline assessments included spirometry, Asthma Control Test (ACT) scores, and corticosteroid usage. Exacerbations, lung function, ACT scores, steroid-sparing effects, and adverse events were recorded monthly over six months. Data were analyzed using independent and paired t-tests, chi-square tests, and repeated measures ANOVA, with significance set at p<0.05. Results: The biologic therapy group demonstrated a significant reduction in mean exacerbation rate over six months (3.1 to 1.2) compared with controls (3.0 to 2.4; p<0.001). FEV₁ improved substantially in the intervention group (61.7% to 72.8% predicted) versus the control group (61.1% to 64.3%; p<0.001). ACT scores increased from 13.4 to 20.1 in the intervention arm compared with 13.0 to 15.2 in controls (p<0.001). Among participants receiving maintenance corticosteroids, 63.6% achieved at least a 50% dose reduction and 27.3% discontinued oral steroids. Mild infections occurred in 16.7% of the intervention group, and two participants experienced minor injection-site reactions, with no severe adverse events reported. Conclusion: The new biologic therapy provided significant improvements in asthma control, lung function, and steroid-sparing effects with minimal adverse events, highlighting its potential as a safe and effective strategy for managing severe asthma in high-risk populations.